Keyword: Pulmocide

Ex-GSK team raises $30M for respiratory infection trials

Researchers who worked at GlaxoSmithKline before leading RespiVert to a takeover by Johnson & Johnson have raised $30.4 million (£24.5 million) for their latest venture, Pulmocide. The Series B will allow Pulmocide to take inhaled treatments for respiratory syncytial virus (RSV) and pulmonary aspergillosis through early clinical trials.